COX-2 Inhibitors and Cancer Therapeutics: Potential Roles for Inhibitors of COX-2 in Combination With Cytotoxic Therapy: Reports From a Symposium Held in Conjunction With the Radiation Therapy Oncology Group June 2001 Meeting

No abstract is available for this paper.

• Publication year

  2003

• Venue

  American Journal of Clinical Oncology

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.COC.0000074180.16144.B3PMID 12902855
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis

  2004cited by this paper
• Celecoxib: a specific COX-2 inhibitor with anticancer properties.

  2002cited by this paper
• Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

  2002cited by this paper
• Approach to angiogenesis inhibition based on cyclooxygenase-2.

  2001cited by this paper
• Mouse by Rofecoxib , a Specific Cyclooxygenase-2 Inhibitor 716 ∆ Apc Chemoprevention of Intestinal Polyposis in the Updated Version

  2001cited by this paper
• Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation

  2001cited by this paper
• Cyclooxygenase-2 is overexpressed in human cervical cancer.

  2001cited by this paper
• COX‐2 is expressed in human pulmonary, colonic, and mammary tumors

  2000cited by this paper
• Host cyclooxygenase-2 modulates carcinoma growth.

  2000cited by this paper
• Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

  2000cited by this paper
• Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

  2000cited by this paper
• Genes expressed in human tumor endothelium.

  2000cited by this paper
• 19 The Logic of Anti-angiogenic Gene Therapy

  1999cited by this paper
• Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

  1999cited by this paper
• Vascular endothelial growth factor: environmental controls and effects in angiogenesis.

  1996cited by this paper
• Blood vessel formation: what is its molecular basis?

  1996cited by this paper
• Angiogenesis as a component of epithelial-mesenchymal interactions.

  1995cited by this paper
• Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

  1995cited by this paper
• Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma.

  1994cited by this paper
• Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.

  1994cited by this paper
• Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues

  1993cited by this paper
• Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents

  1991cited by this paper

• Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia

  2009cites this paper
• Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia

  2008cites this paper
• Molecular markers of radiation-related normal tissue toxicity

  2008cites this paper
• COX-2 Inhibitors in Cancer Cachexia

  2006cites this paper
• The Current Management of Cancer Cachexia

  2006cites this paper
• ORAL ADMINISTRATION OF LUMIRACOXIB REDUCES CHOROIDAL NEOVASCULAR MEMBRANE DEVELOPMENT IN THE RAT LASER-TRAUMA MODEL

  2005cites this paper
• Intratumoral COX-2 Gene Expression Is a Predictive Factor for Colorectal Cancer Response to Fluoropyrimidine-Based Chemotherapy

  2005cites this paper
• Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2.

  2004cites this paper
• Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

  2004cites this paper
• Hypertension, cancer and angiogenesis: Relevant epidemiological and pharmacological aspects

  2004cites this paper
• Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.

  2004cites this paper